HUP0402662A2 - Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk - Google Patents

Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk

Info

Publication number
HUP0402662A2
HUP0402662A2 HU0402662A HUP0402662A HUP0402662A2 HU P0402662 A2 HUP0402662 A2 HU P0402662A2 HU 0402662 A HU0402662 A HU 0402662A HU P0402662 A HUP0402662 A HU P0402662A HU P0402662 A2 HUP0402662 A2 HU P0402662A2
Authority
HU
Hungary
Prior art keywords
cancer
methyl
salts
subject
quinazolin
Prior art date
Application number
HU0402662A
Other languages
English (en)
Inventor
Daniel Tyler Richter
John Charles Kath
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0402662A2 publication Critical patent/HUP0402662A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát képezik az (I) általános képletű E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}allil)acetamid szukcinát- és malonátsói. Közelebbről a találmánytárgyát képezik az (I) általános képletű vegyület szeszkviszukcinát-és dimalonátsói. A találmány tárgyát képezik további az I. általánosképletű vegyület szukcinát- és malonátsóit tartalmazó gyógyászatikészítmények. A találmány szerinti vegyületek alkalmasakhiperproliferatív betegségek, így például rákok - ezen belül példáultüdőrák, nem, csontrák, hasnyálmirigyrák, bőrrák, feji vagy nyaki rák,kután vagy intraokuláris melanóma, méhrák, petefészekrák, végbélrák,endokrinrendszeri rák, pajzsmirigyrák, mellékpajzsmirigy-rák,mellékveserák, lágyszövet-szarkóma, húgycsőrák, péniszrák,prosztatarák stb.- kezelésére emlősökben és különösen emberben,valamint eljárások a fenti sók előállítására. Ó
HU0402662A 2001-12-12 2002-11-11 Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk HUP0402662A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34088501P 2001-12-12 2001-12-12
PCT/IB2002/004708 WO2003050108A1 (en) 2001-12-12 2002-11-11 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer

Publications (1)

Publication Number Publication Date
HUP0402662A2 true HUP0402662A2 (hu) 2005-05-30

Family

ID=23335337

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402662A HUP0402662A2 (hu) 2001-12-12 2002-11-11 Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk

Country Status (34)

Country Link
US (1) US6844349B2 (hu)
EP (1) EP1456199A1 (hu)
JP (1) JP4202926B2 (hu)
KR (1) KR20040065259A (hu)
CN (1) CN1608062A (hu)
AP (1) AP2004003059A0 (hu)
AR (1) AR037772A1 (hu)
AU (1) AU2002366581A1 (hu)
BR (1) BR0214876A (hu)
CA (1) CA2469889A1 (hu)
DO (1) DOP2002000544A (hu)
EA (1) EA007412B1 (hu)
EC (1) ECSP045148A (hu)
GE (1) GEP20063872B (hu)
GT (1) GT200200272A (hu)
HR (1) HRP20040530A2 (hu)
HU (1) HUP0402662A2 (hu)
IL (1) IL161915A0 (hu)
IS (1) IS7227A (hu)
MA (1) MA27095A1 (hu)
MX (1) MXPA04005678A (hu)
NO (1) NO20042925L (hu)
NZ (1) NZ532436A (hu)
OA (1) OA12735A (hu)
PA (1) PA8561401A1 (hu)
PE (1) PE20030716A1 (hu)
PL (1) PL370858A1 (hu)
RS (1) RS46404A (hu)
TN (1) TNSN04112A1 (hu)
TW (1) TW200301103A (hu)
UA (1) UA75482C2 (hu)
UY (1) UY27572A1 (hu)
WO (1) WO2003050108A1 (hu)
ZA (1) ZA200402995B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214499A (pt) * 2001-12-12 2005-05-10 Pfizer Prod Inc Derivados de quinazolina para o tratamento do crescimento anormal das células
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
AU2003303045A1 (en) * 2002-12-18 2004-07-09 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
BR0317259A (pt) * 2002-12-19 2005-11-08 Pfizer Prod Inc Complexos de e-2-metóxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-ilóxi)-fenil amino]- quinazolin-6-il}-alil)-acetamida, seus métodos de produção e utilização
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
MXPA06001989A (es) * 2003-08-18 2006-05-17 Pfizer Prod Inc Programa de dosificacion para un nuevo agente anticanceroso.
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
ATE517622T1 (de) * 2003-10-27 2011-08-15 Merck Sharp & Dohme Salz eines tetrahydropyranylcyclopentyltetrahydropyridopyr diderivats als ccr-2 antagonisten
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
WO2005121124A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same
US7871991B2 (en) 2004-07-27 2011-01-18 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
EP1896030A1 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
JP5544165B2 (ja) * 2006-05-16 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 血液悪性疾患の処置のための方法および組成物
KR20090090336A (ko) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
PL2125786T3 (pl) * 2006-12-21 2011-07-29 Pfizer Prod Inc Bursztynian 2-((4-(1-metylo-4-(pirydyn-4-ylo)-1h-pirazol-3-ilo)fenoksy)metylo)chinoliny
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
PE20091580A1 (es) 2008-03-12 2009-11-05 Takeda Pharmaceutical Compuesto heterociclico fusionado
MX2011000306A (es) * 2008-07-08 2011-03-15 Gilead Sciences Inc Sales de compuestos inhibidores de hiv.
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3960740B1 (en) 2017-08-01 2023-11-15 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
HUP0301120A2 (hu) * 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
CN1608062A (zh) 2005-04-20
DOP2002000544A (es) 2003-06-16
JP2005511744A (ja) 2005-04-28
PE20030716A1 (es) 2003-08-29
MA27095A1 (fr) 2004-12-20
WO2003050108A1 (en) 2003-06-19
IS7227A (is) 2004-04-19
NO20042925L (no) 2004-09-07
TNSN04112A1 (fr) 2006-06-01
MXPA04005678A (es) 2004-12-06
AP2004003059A0 (en) 2004-06-30
GT200200272A (es) 2003-12-12
EA200400674A1 (ru) 2004-10-28
TW200301103A (en) 2003-07-01
RS46404A (en) 2006-10-27
ZA200402995B (en) 2005-04-20
PL370858A1 (en) 2005-05-30
CA2469889A1 (en) 2003-06-19
OA12735A (en) 2006-06-29
KR20040065259A (ko) 2004-07-21
HRP20040530A2 (en) 2004-10-31
PA8561401A1 (es) 2005-02-04
EP1456199A1 (en) 2004-09-15
US20030158217A1 (en) 2003-08-21
ECSP045148A (es) 2004-07-23
JP4202926B2 (ja) 2008-12-24
EA007412B1 (ru) 2006-10-27
UY27572A1 (es) 2003-07-31
IL161915A0 (en) 2005-11-20
NZ532436A (en) 2006-01-27
UA75482C2 (en) 2006-04-17
AR037772A1 (es) 2004-12-01
AU2002366581A1 (en) 2003-06-23
GEP20063872B (en) 2006-07-10
BR0214876A (pt) 2004-12-28
WO2003050108A8 (en) 2003-12-18
US6844349B2 (en) 2005-01-18

Similar Documents

Publication Publication Date Title
HUP0402662A2 (hu) Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk
DE60112942D1 (de) Verbindungen zur behandlung der alzheimerischen krankheit
ATE447970T1 (de) Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
TW200420544A (en) Preparation of substituted quinazolines
PE20010904A1 (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
HK1067128A1 (en) Beta-carbolin derivatives as ptp-inhibitors
YU66100A (sh) N-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat
MXPA05003273A (es) Procedimiento para preparar inhibidores de quinazolina rho-cinasa e intermediarios de los mismos.
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE230989T1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
PL346797A1 (en) Arylsulfonanilide ureas
BRPI0410922B8 (pt) processo para a formação de um composto
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
DK1274692T3 (da) Quinazolinforbindelser
RS51630B (en) 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS β-SECRETASE INHIBITORS (BACE)
MY150219A (en) Process for preparing indol-5-oxy-quinazoline derivatives and intermediates
NO20033746L (no) Fremgangsmåte og blanding for syrebehandling av en underjordisk formasjon
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
ATE440088T1 (de) Verfahren zur herstellung von 4-(3'-chlor-4'- fluoranilino)-7-methoxy-6-(3- morpholinopropoxy)chinazolin
SG165416A1 (en) Chemical process
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
WO2004026814A3 (en) Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors
NL1025072A1 (nl) Complexen van E-2-methoxy-N-(3-{4-[3-methyl-4-(6-methylpyridin-3-yloxy)-fenylamino]- chinazolin-6-yl}-allyl)-aceetamide, werkwijze voor de productie ervan, en toepassing.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees